Over the course of the past several years CCC has endeavoured and made considerable progress in fostering patient and patient group partnerships among stakeholders who have been advocating for their engagement in the clinical trial continuum with the goal of increasing patient access to cancer clinical trials in Canada.
The theme for our 6th Annual Patient-Centered Approach to Clinical Trials Conference is: Disruption and Innovation in Cancer Care. This seminal pan-cancer conference continues to inform clinical trial networks, researchers, industry and academic trial sponsors, HTA agencies, Health Canada, and national and international cancer patient groups, to mention a few.
The 6th edition of this Conference with the theme Disruption and Innovation in Cancer Care is structured as follows:
Dr. Winson Cheung, MD, MPH, FRCPC
A GI medical oncologist, a clinician-scientist, and a cancer health services researcher. From 2010 to 2016, Winson was a clinician-investigator at the BC Cancer Agency in Vancouver. He was recruited to Alberta in 2017. He is currently a Full Professor in the Departments of Oncology, Medicine and Community Health Sciences at the University of Calgary where he is also the Chair and Provincial Director of the Health Services Research Program at Cancer Control Alberta. He conducts comparative effectiveness and population-based outcomes studies across all tumor groups. He is also involved in a number of patient-centric, patient-oriented research projects. He has contributed significantly to building capacity and knowledge generation in the area of real world evidence in oncology. In addition, Winson is the Co-Lead of the Health Systems, Services, and Policy research program at the Canadian Centre for Applied Research in Cancer Control and the Chair of the International Cancer Health Outcomes Research Database Consortium. Previously, he served as Leader for the Health Services Research Track at the American Society of Clinical Oncology Annual Meeting. Recently, he founded the Alberta Cancer Outcomes Research Network.
Alan J. Forster MD, FRCPC, MSc is the Executive Vice President, Chief Innovation and Quality Officer at the Ottawa Hospital, Canada’s largest Academic Health Sciences Center. His focus is enabling teams to create higher value health care – in which patient centered health outcomes are realized and health system costs are lowered.
Over his career, he has led research on patient safety and quality improvement. He performed the seminal work evaluating the incidence of adverse events following discharge from hospital. He has also led the Ottawa Hospital’s data strategy which has been used to support research, operations, and planning. Overall, his work has led to over 240 publications in peer review journals and innumerable advances in quality of care.
In addition to his role at the Ottawa Hospital, Alan is a leader in the field of healthcare quality. He is a Professor of Medicine at the University of Ottawa and Senior Scientist at the Ottawa Hospital Research Institute. He provides ongoing advice to agencies at the local, national, and international levels, and he has served as associated editor for several prestigious peer-review journals.
Craig Lipset is an advisor, educator, advocate and innovator focused on novel solutions for clinical trials and medicine development. He is the founder of Clinical Innovation Partners, providing advisory and board leadership with pharma, tech and investors. Craig is Co-Chair for the Decentralized Trials & Research Alliance, Vice Chair of the MedStar Health Research Institute, and Vice President of the Foundation for Sarcoidosis. He is Adjunct Assistant Professor in Health Informatics at Rutgers University.
Craig was previously the Head of Clinical Innovation and Venture Partner at Pfizer, and on the founding management teams for two successful startup ventures.
Martine Elias is the Executive Director at Myeloma Canada, the only patient-driven, grassroots organization bringing the Canadian myeloma community together and promoting a strong, unified national voice for people living with multiple myeloma. In addition, Martine is the CoChair of the Collective Oncology Network for Exchange, Cancer Care Innovation, Treatment Access and Education (CONECTed), a Canadian based organisation. In 2019 Martine was one of three patient representatives on the PMPRB Guideline Development Steering committee. Martine believes intentional collaboration is key to evolving the knowledge of myeloma for the betterment of patients. In February 2020 she was invited to join the International Myeloma Foundation Board of directors and more recently she was appointed to their Governance and Nominating Committee. She also serves to represent Canada on the Myeloma Patient Europe Community Advisory Board since 2019 where patient advocates address key challenges patients face in accessing diagnosis, monitoring, treatment, care and clinical trial at an international level.
Martine started her career in clinical research in the pharmaceutical industry and has since dedicated her professional life to patient advocacy, empowering the patient voice, and helping patients gain access to essential medical treatments. She is passionate about ensuring that the patient voice is included in all aspects of health policy decisions.
Previously, Martine was Director Access, Advocacy and Community Relations at Myeloma Canada where she developed, led and executed all advocacy strategies and programs.
Prior to that Martine held roles as National Director of Community Relations at Janssen Inc., and Market Access and Health Economics team leader at GSK.